We evaluated 120 leukapheresis procedures (93 patients), in order to detect clinical factors that influence the efficiency of CD34+ collection using Cobe Spectrat cell separators. Hematocrit was 427% and platelet count 430 000/ll in 495% of patients. Platelet transfusions were given if the postprocedure count was o20 000/ll. Multiple regression analysis was used to analyze putative factors, and a predictive equation defined by stepwise regression modeling. The mean efficiency was 0.59 (s.d. 0.27). Sex (M4F; P ¼ 0.01), the volume processed (inversely; P ¼ 0.01) and CD34+ cell count (inversely; P ¼ 0.04) were associated with efficiency, whereas hematocrit, platelet or leukocyte count, catheter type and patient weight were not. The effect size for predictive factors was small (R 2 ¼ 0.21). Adverse events were limited to hypocalcemia. We conclude that female sex, volume processed and CD34+ cell count adversely influence the efficiency of CD34+ cell leukapheresis. However, the impact of volume and CD34+ cell count is small, and likely to be offset by the influence of these same factors on overall yield. Leukapheresis appears to be safe and efficient for autologous blood and marrow transplantation patients with hematocrit 427% and platelet count 430 000/ll.
Autologous blood and marrow transplantation (ABMT) is useful in the treatment of selected patients with hematologic malignancies. In recent years, hematopoietic progenitor cell (HPC) mobilization followed by leukapheresis has almost supplanted bone marrow harvesting as a means of obtaining HPC for ABMT, mainly because it obviates the use of general or spinal anesthesia. At least in theory, peripheral blood HPC collections in patients with bone marrow diseases may also be less contaminated with tumor cells than bone marrow harvests. Studies have also shown that transplants with peripheral blood HPC are associated with faster engraftment and lower costs than those supported by steady-state bone marrow harvests. 1 These advantages of peripheral blood stem cell transplantation (PBSCT) are partly dependent on the number of HPC infused, with CD34+ cell enumeration emerging as the most useful way of quantifying HPC dose. 2 The efficiency of leukapheresis for CD34+ cell collection (Eff CD34 ) has been defined as the number of CD34+ cells collected per volume processed at a given circulating CD34+ cell count. 3 Thus, higher Eff CD34 is valuable in enabling sufficient HPC to be collected in fewer procedures and over a shorter time, minimizing the costs and risks of leukapheresis and graft processing, and potentially translating into safer ABMT. Yet, few studies have focused on identifying the determinants of Eff CD34 , and fewer still have involved Cobe Spectrat apheresis machines, although they are frequently used for this purpose. In one study, focusing on the effects of hematocrit on Eff CD34 , Mehta et al 4 did not find a correlation, although the other existing study, reported by Ford et al, 3 suggested a correlation between hematocrit and Eff CD34 . In both of these studies, however, Fenwal 3000 (Plus) apheresis machines were used. In a more recent study, Mehta et al 5 did not find a relation between Eff CD34 of the Cobe Spectrat machine and the total leukocyte count, and only a modest inverse relation with the circulating CD34+ cell count. That study, however, was not designed to identify other clinical factors that might influence Eff CD34 .
Moreover, as observed by Mehta et al, 4 many institutions (including ours) base leukapheresis eligibility on an arbitrarily chosen preapheresis hematocrit, usually ranging from 25 to 30%. This may lead to delays in leukapheresis while blood transfusions are provided, since a substantial number of patients mobilized with chemotherapy and growth factors for ABMT are likely to be anemic. The determination of a threshold hematocrit above which leukapheresis can be performed safely and with high Eff CD34 would likely reduce the impact of this problem. This is likely to be true for platelet counts also.
We analyzed data collected during leukapheresis with Cobe Spectrat apheresis machines in patients undergoing ABMT in our institution in order to identify preapheresis clinical factors that influence Eff CD34 . We were particularly interested in factors such as the catheter type, volume processed, CD34+ cell or platelet count and hematocrit, which could potentially be manipulated in the future as a way to increase the yield of HPC collections. We also sought to identify a threshold hematocrit and platelet count above which large-volume leukapheresis could be considered safe.
Materials and methods

Patient selection
Between January and December 1999, 93 consecutive patients underwent leukapheresis for collection of HPC as part of University of Maryland at Baltimore Institutional Review Board approved treatment protocols. Informed consent was obtained from all patients. Men (n ¼ 57) outnumbered women (n ¼ 36). Baseline, preleukapheresis laboratory results of the patients are shown in Table 1 . The mean patient weight was 71.56 kg (s.d. 13.52). Staggeredport catheters were used in 29 patients, and nonstaggeredport catheters in 60 patients, while peripheral veins or an unknown, previously placed catheter type was used in four patients. Two patients had platelet counts less than 20 000/ ml prior to leukapheresis, and were processed as planned deviations from our standard operating procedure. The mean volume processed was 22.8 l (s.d. 7.1 l).
Procedures
Mobilization consisted of treatment with cyclophosphamide with or without etoposide, followed by GCSF 10 mg/ kg or GMCSF 250 mg/m 2 administered subcutaneously once a day. Four patients, who failed to obtain enough circulating CD34+ cells to undergo leukapheresis, underwent a second attempt using a combination of GCSF 10 mg/ kg and GMCSF 250 mg/m 2 without chemotherapy, beginning at least 3 weeks after the initial mobilization attempt. Circulating CD34+ cell counts, determined by flow cytometry (ProCOUNT, Becton Dickinson, San Jose, CA, USA), were followed when the leukocyte count recovered to 42000/ml after mobilization, and leukapheresis was begun when the CD34+ cell count exceeded 20-40/ml or was felt to have peaked. Each patient's transplant physician prescribed the target CD34+ cell number to be collected. Since ABMT protocols in our institution during this period were designed to deliver multiple cycles of posttransplant chemotherapy, the target dose often exceeded 5-10 million CD34+ cells/kg so that back-up cells could be stored. Cobe Spectrat apheresis machines (Gambro BCT, Lakewood, CO, USA) were used throughout, in the mononuclear cell collection configuration; flow rates and collection port location in the leukapheresis centrifuge were adjusted manually using the color chart provided by the manufacturer. Large-volume leukapheresis (up to 30 l at peak flow rates of 125 ml/min) was employed. Leukapheresis was repeated the next day if an insufficient number of CD34+ cells was obtained. Conversely, in those patients whose high CD34+ cell count predicted for adequate yields at smaller volumes, the duration of apheresis (rather than flow rates) was reduced. Anticoagulant consisted of ACDA (970 ml) plus heparin (10 000 ml), with an AC ratio of 30:1. Calcium supplements (oral or by central vein) were given only if symptoms of hypocalcemia appeared. The type of central venous catheter used for leukapheresis, classified as having staggered (Bard-Hickman apheresis; Bard, Salt Lake City, UT, USA) or nonstaggered (Neostar; Horizon Medical Products, Manchester, GA, USA) ports, was based on treating physician preference and was not decided by apheresis personnel. The Eff CD34 was defined in this study as Total # CD34þ cells collected Circulating CD34þ cell countÂnumber of liters processed All computations were based on complete blood counts and circulating CD34+ cell counts obtained on the morning of apheresis. Thrombocytopenia and anemia were not considered to be contraindications to leukapheresis provided the platelet count and hematocrit were greater than 20 000/ml and 25%, respectively. Instead, our standard operating procedure was to measure the complete blood count again after leukapheresis, and administer a platelet transfusion if the count was less than 20 000/ml. The CD34+ progenitor cell content of apheresis products was measured using a dual platform flow cytometric method (FACSCAN, Becton Dickinson, San Jose CA, USA) as previously described. 6 In order not to confound the analysis for patient-related (as distinct from procedure-related) factors, only the first apheresis procedure for each patient was included in the primary analysis. However, to gain some independent measure of the variation in Eff CD34 between procedures rather than between patients, a separate analysis was conducted using pairs of data sets obtained from patients who had more than one apheresis procedure. No interim analyses were performed, and the results of Eff CD34 were not reported to apheresis staff until completion of the study.
Statistical methods
The correlation between Eff CD34 and various preleukapheresis factors was measured by computing Spearman's correlation coefficients. The Mann-Whitney test or Kruskal-Wallis test was used to determine differences between groups. Multiple linear regression analysis was performed to explore the joint association between Eff CD34 and all the factors that were identified in the univariate analysis. A stepwise regression model was then used to derive an equation for prediction of Eff CD34 . The factors analyzed in the regression analysis were gender, catheter type, hematocrit, weight, and leukocyte, platelet and CD34+ cell count, all pertaining to the first leukapheresis procedure. In patients who had more than one procedure, the percentage change in Eff CD34 between the first and second procedure Three factors -sex, volume processed and CD34+ cell count -were found to be significantly associated with Eff CD34 . Men had a 13.8% higher Eff CD34 than women (P ¼ 0.01) (Figure 2 ). The volume processed was negatively associated with Eff CD34 , with each liter increase in volume reducing Eff CD34 by 1.3% (P ¼ 0.01). The CD34+ cell count was also negatively associated with Eff CD34 , so that an increase of 10/ml in CD34+ cell counts translated to a decrease of 0.3% in Eff CD34 (P ¼ 0.04). The catheter type, leukocyte count and hematocrit did not show a relation with efficiency. The platelet count showed a (statistically insignificant) trend towards a negative association with Eff CD34 , with each 10 000/ml increase in platelet count resulting in a 0.6% reduction in Eff CD34 (P ¼ 0.06%). Among patients who had two procedures (n ¼ 26), the percentage change in CD34+ cell count between the first and second procedure was negatively correlated with the change in Eff CD34 (P ¼ 0.002), with none of the other variables showing a significant relation.
Discussion
A high Eff CD34 of leukapheresis implies that sufficient CD34+ cells for an ABMT can be collected using fewer leukapheresis sessions or shorter time on the machine. This is likely to reduce the risks and costs of this phase of ABMT. In this study, we sought to identify factors that might be correlated with Eff CD34 , as well as to help define ranges of hematocrit and platelet count over which large volume leukapheresis could be considered safe.
The Eff CD34 of a Cobe Spectrat apheresis machine used as a CD34+ cell collector depends in part on the ability of the collection port to be kept within the target cell layer produced by continuous blood centrifugation in the extracorporeal circuit. The operator guides this by matching the layers in the centrifuged blood in the machine with a color chart provided by the manufacturer. Thus, a steady and distinct laminar separation of blood during centrifugation, with a high concentration of CD34+ cells in the (target) mononuclear cell layer would be expected to translate into high Eff CD34 . These operating characteristics are likely to be influenced by the physical properties of the donor's blood (because of factors such as the hematocrit, leukocyte count and viscosity) as well as the CD34+ and mononuclear cell counts. The Eff CD34 of large volume leukapheresis may also be affected by the distance between the inflow and return ports in the apheresis catheter, since recirculation of blood might occur at high flow rates. It is less intuitive that an individual's sex might have an influence on leukapheresis Eff CD34 . Other operating characteristics pertaining to the mechanics of the cell separator, such as centrifuge speed, collection port diameter, etc are not usually controlled by the operator, and were not the subject of this study.
The mean Eff CD34 of 0.5970.27 obtained in our study compares favorably with the value of 0. 4, 5 in their study, made the interesting observation that Eff CD34 appeared to improve with time. The Eff CD34 increased from 36.1% in the first 24 patients, to 54.4% in the next 37 procedures. The value of 54.4% obtained in their latter group of procedures is similar to those obtained by us and by Stroncek et al. 7 In our institution, Cobe Spectrat machines have been used exclusively since 1993 for stem cell collection (now 4150 procedures a year), and even before that for therapeutic leukapheresis and apheresis, granulocyte and platelet collection. It is probable that, as observed by Mehta et al, 4, 5 Eff CD34 with this machine does improve with time and experience, so that the differences in mean efficiency obtained in the different studies might be reflective of operator skill rather than differences in study methodology, especially with use of manual rather than automated cell collection protocols.
In our analysis, female gender, volume processed, and CD34+ cell count were all associated with a decrease in the Eff CD34 of large volume leukapheresis, whereas the hematocrit, leukocyte count, platelet count and catheter type had no effect. The relation of these variables with Eff CD34 could be described in a mathematical equation. Ford et al 3 were the first to fit Eff CD34 to a predictive formula of this kind, although in their study, using a different apheresis machine, the leukocyte count, hematocrit, and serum albumin were the predictive factors: In our study, as in theirs, the amount of variation in Eff CD34 explained by the contributing variables was clinically relevant although small (as shown by R 2 of 0.27 and 0.21). This suggests that other, as yet undetermined factors might be playing an important role. The small effect size also means that any changes in the CD34+ cell count and volume processed are likely to be overcome by the larger effects of these same variables on the actual CD34+ cell yield. The CD34+ cell count retained its significance when we compared Eff CD34 between different leukapheresis procedures in the same patient. This analysis reduced the effect of patient-related confounding factors. Mehta et al
and Heuft et al
8 also demonstrated an inverse relation between CD34+ cell count and Eff CD34, although this was not the case in the study reported by Ford et al. 9 One speculative explanation for the relation between Eff CD34 and CD34+ cell counts might be that at high CD34+ cell counts, the collection port in the leukapheresis centrifuge fails to capture as great a proportion of these important cells as at relatively lower CD34+ cell counts. In our study, almost all patients were mobilized with fairly intensive chemotherapy, and the day of collection was based on CD34+ cell counts. This led to a very wide range of CD34+ cell counts among patients, so that the effect of this variable would be easy to detect.
An inverse relation was also demonstrated between the volume processed and Eff CD34 . A similar relation was demonstrated in one study in which Fenwal CS 3000 apheresis machines were used. 10 This observation might imply a limited volume of distribution of CD34+ cells, with CD 34+ cell counts declining during leukapheresis. In general, apheresis of a purely intravascular product is limited by the volume processed, so that processing of more than 1.5 times the plasma volume is not productive and efficiency tails off with increasing volume processed. On the other hand, with a product that is continuously replenished from extravascular sources, continued apheresis is productive, so that the efficiency is stable with respect to volume. Mathematically, this difference is accounted for by assuming a larger (or indefinite) volume of distribution for products that are continuously replaced in the intravascular space during apheresis. Which model more closely fits the collection of CD34+ cells by leukapheresis remains controversial. The fact that an Eff CD34 41.0 can be calculated in some cases where more than 1.5 plasma volumes were processed, suggests that the CD34+ cell count actually increased during those procedures, a phenomenon that has been termed 'apheresis recruitment'. This has been observed in some but not all studies of adults and children undergoing leukapheresis for CD34+ cells.
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Schlenke et al, 10 after observing a similar inverse relation between Eff CD34 and volume processed, showed that the size of that effect could be diminished by using an improved formula for Eff CD34 that accounted for the total number of CD 34+ cells existing at the end of the procedure. The mean efficiencies calculated by using that method, however, did not differ from those obtained with the standard formula, although the variation was less, and no instances of Eff CD34 41 were observed. 10 We did not use that formula for efficiency because it would have required measuring the CD34+ cell count again after each leukapheresis procedure.
It is not clear to us why the Eff CD34 was higher in men than in women. Perhaps this may relate to the generally larger blood and plasma volumes in men, as compared to women of the same weight.
It is important to note the absence of a relation between Eff CD34 and catheter type, leukocyte count, hematocrit, platelet count, or patient weight. Catheters with staggered ports might be preferred because of the theoretical concern with recirculation, although this has not been conclusively demonstrated to our knowledge. The present study shows, however, that the use of catheters with nonstaggered ports does not diminish Eff CD34 . If this is confirmed in other studies, then in the future catheters might be selected based on factors other than port location.
One previous study found a relation between hematocrit and leukapheresis Eff CD34 ; however, in that study a different leukapheresis machine (Fenwal CS 3000 Plus) and technique were used. 3 Other studies, 4 including one in which Cobe Spectrat machines were also evaluated, 9 have not shown an important relation with hematocrit. It is possible that the close range of hematocrits (standard deviation of 3.2; see Figure 2 ) among our patients limited the ability to detect a correlation with Eff CD34 .
The lack of a relation between Eff CD34 and leukocyte counts is in agreement with the findings of Mehta et al.
5
Higher leukocyte counts, however, appear to predict lower Eff CD34 of the Fenwal machine. 3, 5 In practice, the negative effect of a high leukocyte count on Eff CD34 can usually be Determinants of CD34+ cell leukapheresis efficiency C Sarkodee-Adoo et al overcome by processing a larger volume if the circulating CD34+ cell count is high. However, in cases where the CD34+ cell count is marginal or where the processing of larger volumes is not feasible, the Cobe Spectrat may be preferred to the Fenwal CS 3000 plus for CD34+ cell collection. Leukapheresis procedures are usually accompanied by a fall in the platelet count, because of the inability to exclude platelets from the target cell layer in the centrifuge. This, together with the hemorrhagic risk introduced by anticoagulants that may enter the corporal circuit, increases the bleeding risk in patients whose platelet counts are already low before leukapheresis. Thus, many centers appropriately regard severe thrombocytopenia as a relative contraindication to large-volume leukapheresis, and will transfuse such patients with platelets before the procedure. However, little or no data is available to guide the selection of a specific threshold platelet count for this purpose. In addition, many institutions base leukapheresis eligibility in part on the preapheresis hematocrit, in accordance with the requirements of accreditation and regulatory agencies to define such limits. Mehta et al 4 have shown recently that Eff CD34 of the Fenwal CS 3000 (Plus) is not compromised by a low hematocrit. 4 In the present study, we also did not find a correlation with the Cobe Spectrat device, and moreover did not observe major adverse reactions (other than hypocalcemic symptoms) in this group of patients, most of whom were anemic or thrombocytopenic during leukapheresis. More than 95% of the patients, however, had an hematocrit 427% and platelet count 430 000/ml. These findings may provide some guidance in the selection of threshold parameters for initiating leukapheresis. It is important to emphasize, however, that in our institution platelet transfusions were immediately available if any patient had needed them, and patients with postleukapheresis platelet counts less than 20 000/ml were transfused before discharge.
In summary, the findings of this study argue against a significant influence of catheter type, hematocrit, platelet or leukocyte count on the safety and Eff CD34 of leukapheresis for CD34+ cells, whereas sex, the volume of apheresis and circulating CD34+ count all showed modest but independent effects on Eff CD34 . The effects of leukapheresis volume and CD34+ cell count were small, and in practice are likely to be overcome by the more significant influence of these same variables on the actual yield of CD34+ cells. Baseline thrombocytopenia (mean 84 000/ml; s.d. ¼ 53) and anemia (mean hematocrit 30.7; s.d. ¼ 3.3) also appeared to be safe for leukapheresis, with platelet transfusions restricted to those with postleukapheresis platelet count less than 20 000/ml.
